Strict glycemic control, as well as blockade of the renin-angiotensin axis, are the two main management modalities for DN and despite these measures, a considerable number of DN patients progress to ESRD, underlining the importance of developing novel adjunctive therapeutic agents for DN (2). Here, REN is linked to liver dysplastic nodule.